Erratum: Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: The dual antiplatelet therapy randomized clinical trial (JAMA (2015) 313:11 (1113-1121) DOI 10.1001/jama.2015.1671);Antiplatelet therapy duration following bare metal or drug-eluting coronary stents

JAMA - Journal of the American Medical Association

Volumn 313, Issue 11, 2015, Pages 1113-1121

  Kereiakes, Dean J ^a,b   Yeh, Robert W ^c,d   Massaro, Joseph M ^c,e   Driscoll Shempp, Priscilla ^c   Cutlip, Donald E ^c,f   Steg, P Gabriel ^g,h,i   Gershlick, Anthony H ^j   Darius, Harald ^k   Meredith, Ian T ^l   Ormiston, John ^m   Tanguay, Jean Francois ⁿ   Windecker, Stephan ^o   Garratt, Kirk N ^p   Kandzari, David E ^q   Lee, David P ^r   Simon, Daniel I ^s   Iancu, Adrian Corneliu ^t   Trebacz, Jaroslaw ^u   Mauri, Laura ^c,v  

^a CHRIST HOSPITAL   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON UNIVERSITY   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h BICHAT HOSPITAL   (France)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^k Vivantes Neukoelln Medical Center   (Germany)

^l Monash Heart   (Australia)

^m Mercy Hospital   (New Zealand)

ⁿ MONTREAL HEART INSTITUTE   (Canada)

^o UNIVERSITY OF BERN   (Switzerland)

^p LENOX HILL HOSPITAL   (United States)

^q PIEDMONT HEART INSTITUTE   (United States)

^r STANFORD UNIVERSITY   (United States)

^s UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^t HEART INSTITUTE   (Romania)

^u Jan Pawel II Hospital   (Poland)

^v BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY STENTING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIROLIMUS ELUTING CORONARY STENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; ZOTAROLIMUS ELUTING CORONARY STENT; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY RESTENOSIS; DRUG COMBINATION; DRUG ELUTING STENT; INTENTION TO TREAT ANALYSIS; RISK; STENT;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RISK; STENTS;

EID: 84925883908     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.4806     Document Type: Erratum

References (22)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [published correction appears in Circulation. 2012;125(8):e412]. Circulation. 2011;124 (23):e574-e651.
2. Windecker S, Kolh P, Alfonso F, et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7): 494-502.
4. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166.
5. Valgimigli M, Campo G, Monti M, et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-2026.
6. Badheka AO, Arora S, Panaich SS, et al. Impact on in-hospital outcomes with drug-eluting stents versus bare-metal stents (from 665, 804 procedures). Am J Cardiol. 2014;114(11):1629-1637.
7. Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly persons: results from 262, 700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol. 2009;53(18):1629-1641.
8. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035-1041.
9. Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: the GUSTO investigators. N Engl J Med. 1993;329(10):673-682.
11. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-2747.
12. Ellis SG, Vandormael MG, Cowley MJ, et al; Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82(4):1193-1202.
13. Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010;3(5): 468-475.
14. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110(10):1226-1230.
15. Chacko R, Mulhearn M, Novack V, et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC Cardiovasc Interv. 2009;2(6):498-503.
16. Takano M, Yamamoto M, Mizuno K. Two cases of coronary stent thrombosis very late after bare-metal stenting. JACC Cardiovasc Interv. 2009; 2(12):1286-1287.
17. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151(6): 1260-1264.
18. Kereiakes DJ, Yeh RW, Massaro JM, et al. Comparison of ischemic events after drug-eluting stents or bare metal stents in subjects receiving dual antiplatelet therapy: results from the randomized Dual Antiplatelet Therapy Study [abstract]. Circulation. 2014;130(23):2113.
19. Gilard M, Barragan P, Noryani AA, et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial [published online November 16, 2014]. J Am Coll Cardiol. doi:10.1016/j.jacc.2014.11.008.
20. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505-513.
21. Feres F, Costa RA, Abizaid A, et al; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310(23):2510-2522.
22. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64(20):2086-2097.